Whitehawk Therapeutics (WHWK) EBIAT (2018 - 2025)
Historic EBIAT for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$17.7 million.
- Whitehawk Therapeutics' EBIAT fell 4144.75% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 7467.01%. This contributed to the annual value of -$63.7 million for FY2024, which is 314.0% up from last year.
- Latest data reveals that Whitehawk Therapeutics reported EBIAT of -$17.7 million as of Q3 2025, which was down 4144.75% from -$52.6 million recorded in Q2 2025.
- Over the past 5 years, Whitehawk Therapeutics' EBIAT peaked at $73.0 million during Q1 2025, and registered a low of -$87.1 million during Q3 2021.
- Over the past 5 years, Whitehawk Therapeutics' median EBIAT value was -$16.0 million (recorded in 2021), while the average stood at -$15.7 million.
- Per our database at Business Quant, Whitehawk Therapeutics' EBIAT tumbled by 291134.16% in 2021 and then skyrocketed by 49899.45% in 2025.
- Whitehawk Therapeutics' EBIAT (Quarter) stood at -$16.0 million in 2021, then increased by 13.04% to -$13.9 million in 2022, then dropped by 16.91% to -$16.3 million in 2023, then dropped by 12.4% to -$18.3 million in 2024, then grew by 2.93% to -$17.7 million in 2025.
- Its last three reported values are -$17.7 million in Q3 2025, -$52.6 million for Q2 2025, and $73.0 million during Q1 2025.